What liver work‑up should be performed in a patient with severe alpha‑1 antitrypsin deficiency (PiZZ genotype or serum A1AT < 50 mg/dL)?

Liver Work-Up for Severe Alpha-1 Antitrypsin Deficiency

All patients with severe AATD (PiZZ genotype or serum A1AT < 50 mg/dL) should undergo baseline liver assessment with liver function tests (AST, ALT, GGT, bilirubin), platelet count, and vibration-controlled transient elastography (VCTE/FibroScan®), followed by regular monitoring even in the absence of symptoms.

Initial Assessment

Baseline Laboratory Testing

• Liver enzymes: AST, ALT, and gamma-glutamyl transferase (GGT) 1
• Platelet count: Essential for calculating fibrosis scores 2
• Bilirubin: Part of standard liver function assessment 1

Important caveat: Liver enzymes may be normal or only mildly elevated in AATD patients, even in the presence of significant liver disease 3. Do not rely solely on normal liver enzymes to exclude liver involvement.

Non-Invasive Fibrosis Assessment

VCTE (FibroScan®) is the preferred initial non-invasive test for assessing liver fibrosis in AATD patients 4, 2. This recommendation is based on:

• High accessibility and reliability
• Excellent feasibility (97% technical success rate) 5
• Strong diagnostic and prognostic utility (AUROC ≥ 0.90 for predicting major adverse liver outcomes) 3

VCTE Interpretation Thresholds:

• < 8 kPa: No or mild fibrosis (likely < F2) 4, 2
• ≥ 8 kPa: Clinically significant fibrosis (≥ F2 on METAVIR scale) 4, 2
• ≥ 13 kPa: Probable cirrhosis 4

Blood-Based Fibrosis Scores

Calculate these complementary markers:

• AST-to-Platelet Ratio Index (APRI): < 0.5 indicates low risk for advanced disease 2
• Fibrosis-4 (FIB-4) score: < 1.3 indicates low risk for advanced disease 2

Note: While these scores have excellent prognostic value for major adverse liver outcomes 3, their sensitivity is limited 2. Use them in conjunction with VCTE, not as standalone tests.

Imaging

Abdominal ultrasound should be performed as part of the initial assessment 1. Look for:

• Liver texture and echogenicity
• Signs of cirrhosis (nodular contour, splenomegaly)
• Portal hypertension features
• Hepatocellular carcinoma screening in older patients

Preventive Measures

All AATD patients should receive 1:

• Hepatitis A vaccination
• Hepatitis B vaccination

These are critical because viral hepatitis may accelerate liver disease progression, particularly in heterozygotes 1.

Ongoing Monitoring Strategy

For Patients Without Significant Fibrosis (VCTE < 8 kPa):

• Regular liver function tests: Annually or as clinically indicated 1
• Repeat VCTE: Every 2-3 years or if liver enzymes become abnormal

For Patients With Clinically Significant Fibrosis (VCTE ≥ 8 kPa):

• Liver function tests: Every 6-12 months 1
• VCTE: Annually to monitor progression 2
• Ultrasound: Every 6-12 months 1
• Consider magnetic resonance elastography (MRE) or enhanced liver fibrosis (ELF) test for additional assessment 4

For Patients ≥ 50 Years With Decompensated Cirrhosis:

• CT imaging of the liver: Periodically for hepatocellular carcinoma surveillance 1
• Alpha-fetoprotein measurement is insensitive and should not be relied upon alone 1

When to Consider Liver Biopsy

Liver biopsy is NOT indicated for diagnosing AATD 1. Its role is confined to:

• Staging liver disease in patients with clinically overt liver disease
• Evaluating patients being considered for clinical trials or specific interventions 2

The incidental finding of periodic acid-Schiff-positive globules on liver biopsy should prompt AATD testing if not already diagnosed 1.

Critical Clinical Pearls

Age-Related Considerations:

• Elderly patients (≥ 50 years) without liver symptoms still require regular liver function test monitoring 1
• Peak incidence of cirrhosis occurs in elderly never-smokers who survived without severe emphysema 1

Gender Considerations:

• Male sex confers increased risk for developing cirrhosis in PiZZ individuals 1

Heterozygotes (PiMZ, PiSZ):

• Much smaller cirrhosis risk than homozygotes 1
• Alcohol and hepatitis C are potential risk factors 1
• Plasma AAT levels may be normal during active liver disease; phenotyping by isoelectric focusing is required for diagnosis 1

Augmentation Therapy:

Intravenous AAT augmentation therapy does NOT benefit liver disease 1. It is indicated only for lung disease management. Recent data suggest it may be liver-safe and potentially associated with less pronounced fibrosis 6, but this requires prospective validation.

Pediatric Considerations:

• PiZZ is a common cause of neonatal cholestasis 1, 7
• Most cases resolve spontaneously, but AATD remains a frequent indication for pediatric liver transplantation 1
• Liver enzyme abnormalities are common in early life 1

Referral Indications

Refer to hepatology when:

• VCTE ≥ 8 kPa (clinically significant fibrosis)
• Persistently abnormal liver enzymes
• Any signs of decompensated liver disease
• Consideration for liver transplantation evaluation 2

This algorithmic approach ensures systematic detection and monitoring of liver involvement in AATD, enabling timely intervention and appropriate surveillance for complications including hepatocellular carcinoma.